This fund manager isn’t big on ‘Mag 7’ tech stocks. But he likes these ‘Mag 2.’
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2025
0mins
Should l Buy BDX?
Source: MarketWatch
Market Sentiment: The recent panic among stock investors and the volatile reaction to the Trump administration's tariff pause suggests it may be a good time to explore investment opportunities in the market.
Expert Insight: David Giroux, a seasoned manager at T. Rowe Price Capital Appreciation Fund, is consulted for advice on stocks and sectors worth considering during this uncertain period.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BDX
Wall Street analysts forecast BDX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 202.38 USD with a low forecast of 183.00 USD and a high forecast of 220.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
3 Buy
5 Hold
0 Sell
Moderate Buy
Current: 210.020
Low
183.00
Averages
202.38
High
220.00
Current: 210.020
Low
183.00
Averages
202.38
High
220.00
About BDX
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, and more. Its BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, advanced monitoring, and pharmaceutical systems. Its BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. Its BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Market Sentiment Improves as Nasdaq Rises Over 200 Points
- Sentiment Recovery: The CNN Money Fear & Greed Index rose to 48.3 on Monday, entering the 'Neutral' zone from a previous reading of 43.9, indicating improved market sentiment that may attract more investors.
- Broad Market Gains: U.S. stocks mostly closed higher on Monday, with the Nasdaq Composite jumping over 200 points to 23,238.67, suggesting strong performance in tech stocks driving overall market positivity.
- Dow Jones Record High: The Dow Jones index increased by about 20 points to 50,135.87 on Monday, marking a new record, reflecting enhanced investor confidence in economic recovery that could further propel market growth.
- Sector Performance Divergence: While most sectors in the S&P 500 closed positively, with materials, energy, and information technology stocks leading gains, consumer staples and healthcare stocks fell, indicating a divergence in market performance that may influence investor decisions.
See More
US Stocks Rise on Monday as Tech Stocks Rebound
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
See More
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
Becton Dickinson Reports Strong Q1 2026 Earnings Exceeding Expectations
- Strong Performance: Becton Dickinson reported Q1 revenues of $5.3 billion, reflecting a 0.4% year-over-year growth, with New BD achieving a 2.5% increase, showcasing robust performance in biologic drug delivery and pharmacy automation, thereby reinforcing its market position.
- Margin Performance: The adjusted gross margin stood at 53.4%, down 140 basis points from the previous year, yet still above expectations, indicating the company's ongoing efforts in productivity and cost control to maintain profitability stability.
- Strategic Transaction: The company announced the imminent completion of its Life Sciences business merger with Waters, expected to yield a $4 billion cash distribution, with $2 billion allocated for share repurchases and $2 billion for debt repayment, further optimizing its capital allocation strategy.
- Future Outlook: Management anticipates low single-digit revenue growth for New BD in fiscal 2026, providing adjusted EPS guidance in the range of $12.35 to $12.65, reflecting confidence in future performance despite tariff impacts.
See More
Credo Technology Raises Revenue Guidance Significantly
- Revenue Guidance Increase: Credo Technology expects to report revenue between $404 million and $408 million, significantly up from prior guidance of $335 million to $345 million, indicating strong market demand and business growth potential.
- Significant Year-over-Year Growth: The company anticipates over 200% year-over-year growth in the current fiscal year, reflecting its competitive position in the industry and rapid market share expansion.
- Quarterly Growth Outlook: Credo also expects mid-single-digit sequential revenue growth to round out the year, suggesting continued strong performance in the coming months, which enhances investor confidence.
- Positive Stock Reaction: In pre-market trading, Credo Technology shares jumped 17.4% to $144.87, reflecting market optimism regarding its financial outlook and potentially attracting more investor interest.
See More
Market Sentiment Improves as Nasdaq Rises Over 200 Points
- Sentiment Recovery: The CNN Money Fear & Greed Index rose to 48.3 on Monday, entering the 'Neutral' zone from a previous reading of 43.9, indicating improved market sentiment that may attract more investors.
- Broad Market Gains: U.S. stocks mostly closed higher on Monday, with the Nasdaq Composite jumping over 200 points to 23,238.67, suggesting strong performance in tech stocks driving overall market positivity.
- Dow Jones Record High: The Dow Jones index increased by about 20 points to 50,135.87 on Monday, marking a new record, reflecting enhanced investor confidence in economic recovery that could further propel market growth.
- Sector Performance Divergence: While most sectors in the S&P 500 closed positively, with materials, energy, and information technology stocks leading gains, consumer staples and healthcare stocks fell, indicating a divergence in market performance that may influence investor decisions.
See More
US Stocks Rise on Monday as Tech Stocks Rebound
- Market Recovery: The S&P 500 Index rose by 0.47% on Monday, with the Dow Jones Industrial Average hitting an all-time high, indicating a strong recovery in the market following rebounds in tech stocks and chipmakers, reflecting investor confidence in economic recovery.
- Precious Metals Surge: Mining stocks rallied as gold prices increased by 2% and silver surged over 6%, with Coeur Mining and Hecla Mining gaining more than 7% and 5% respectively, highlighting the positive impact of strong performance in the precious metals market on related stocks.
- Earnings Season Insights: More than half of S&P 500 companies have reported earnings, with 79% exceeding expectations, and Q4 earnings growth projected at 8.4%, which is likely to further boost market sentiment and enhance investor confidence.
- Economic Data Focus: The market will closely watch upcoming economic data releases, including the employment cost index and retail sales figures, which are expected to significantly influence future monetary policy and market trends.
See More
Kyndryl Shares Plunge 54% Amid Heavy Trading
- Stock Price Plunge: Kyndryl shares fell 54% amid heavy trading, reflecting strong market concerns regarding the company's financial health, which could lead to diminished investor confidence and impact future financing capabilities.
- Surge in Trading Volume: The trading volume for Kyndryl's stock significantly increased during this period, indicating that investors are highly sensitive to the company's financial reports, which may trigger further market volatility.
- Financial Report Impact: The company's fiscal Q3 financial report released on Monday failed to meet market expectations, resulting in a substantial drop in stock price that could affect its future business development and strategic planning.
- Investor Confidence Shaken: The sharp decline in Kyndryl's stock price may shake investor confidence in its long-term growth potential, thereby impacting its market position and competitiveness.
See More
US Stocks Rebound as Tech Shares Recover
- Market Recovery: The S&P 500 Index rose by 0.46%, the Dow Jones Industrial Average increased by 0.09%, and the Nasdaq 100 climbed by 0.61%, indicating a rebound in the market driven by recovering tech and chipmaker stocks, reflecting investor confidence in economic growth.
- Mining Stocks Surge: Gold prices increased by over 1% and silver prices jumped more than 6%, boosting mining stocks with Coeur Mining up over 6% and Freeport McMoRan up more than 5%, suggesting rising investor demand for precious metals amid inflation concerns.
- Positive Earnings Outlook: Over 79% of S&P 500 companies that reported earnings exceeded expectations, with Q4 earnings growth projected at 8.4%, marking the tenth consecutive quarter of year-over-year growth, indicating sustained corporate profitability that could further drive stock market gains.
- Economic Data Focus: The market is closely watching upcoming employment and inflation data, with January nonfarm payrolls expected to rise by 69,000 and the unemployment rate to remain at 4.4%, as these figures will influence investor expectations regarding future monetary policy, potentially leading to market volatility.
See More
Becton Dickinson Reports Strong Q1 2026 Earnings Exceeding Expectations
- Strong Performance: Becton Dickinson reported Q1 revenues of $5.3 billion, reflecting a 0.4% year-over-year growth, with New BD achieving a 2.5% increase, showcasing robust performance in biologic drug delivery and pharmacy automation, thereby reinforcing its market position.
- Margin Performance: The adjusted gross margin stood at 53.4%, down 140 basis points from the previous year, yet still above expectations, indicating the company's ongoing efforts in productivity and cost control to maintain profitability stability.
- Strategic Transaction: The company announced the imminent completion of its Life Sciences business merger with Waters, expected to yield a $4 billion cash distribution, with $2 billion allocated for share repurchases and $2 billion for debt repayment, further optimizing its capital allocation strategy.
- Future Outlook: Management anticipates low single-digit revenue growth for New BD in fiscal 2026, providing adjusted EPS guidance in the range of $12.35 to $12.65, reflecting confidence in future performance despite tariff impacts.
See More
